Trial reportMolecular psychiatry2012
Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study.
Trial report in Molecular psychiatry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 66 citations in OpenAlex.
- A positron emission tomography occupancy study of brexpiprazole at dopamine DNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Trial
- Measuring endogenous changes in serotonergic neurotransmission with [Translational psychiatry · 2019Trial
- The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram.Progress in neuro-psychopharmacology & biological psychiatry · 2018Trial
- Serotonin reuptake inhibitors and serotonin transporter genotype modulate performance monitoring functions but not their electrophysiological correlates.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Trial
- Serotoninergic effects on judgments and social learning of trustworthiness.Psychopharmacology · 2014Trial
- The relationship between reward and punishment processing and the 5-HT1A receptor as shown by PET.Psychopharmacology · 2014Trial
- Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study.Molecular psychiatry · 2014Trial
- Dopamine modulates reward-related vigor.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Trial
- Dynamics of human serotonin synthesis differentially link to reward anticipation and feedback.Molecular psychiatry · 2025Article
- Pharmacological manipulation of neurotransmitter activity induces disparate effects on cerebral blood flow and resting-state fluctuations.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- [European journal of nuclear medicine and molecular imaging · 2023Article
- Fifty years on: Serotonin and depression.Journal of psychopharmacology (Oxford, England) · 2023Review
- [Frontiers in neuroscience · 2021Article
- Inverse changes in raphe and cortical 5-HTSynapse (New York, N.Y.) · 2020Article
- Serotonin release measured in the human brain: a PET study with [Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging.Medicinal research reviews · 2019Review
- Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience.Frontiers in medicine · 2019Review
- Functional Connectivity of the Raphe Nuclei: Link to Tobacco Withdrawal in Smokers.The international journal of neuropsychopharmacology · 2018Article
- Serotonin concentration enhancers at clinically relevant doses reduce [Translational psychiatry · 2018Article
- Cerebral serotonin release correlates with [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
Serotonin (5-HT) neurotransmission is implicated in cognitive and emotional processes and a number of neuropsychiatric disorders. The use of positron emission tomography (PET) to measure ligand displacement has allowed estimation of endogenous dopamine release in the human brain; however, applying this methodology to assess central 5-HT release has proved more challenging. The aim of this study was to assess the sensitivity of a highly selective 5-HT(1A) partial agonist radioligand [(11)C]CUMI-101 to changes in endogenous 5-HT levels induced by an intravenous challenge with the selective 5-HT re-uptake inhibitor (SSRI), citalopram, in healthy human participants. We studied 15 healthy participants who underwent PET scanning in conjunction with [(11)C]CUMI-101 after receiving an intravenous infusion of citalopram 10 mg or placebo in a double-blind, crossover, randomized design. Regional estimates of binding potential (BP(ND)) were obtained by calculating total volumes of distribution (V(T)) for presynaptic dorsal raphe nucleus (DRN) and postsynaptic cortical regions. Relative to placebo, citalopram infusion significantly increased [(11)C]CUMI-101 BP(ND) at postsynaptic 5-HT(1A) receptors in several cortical regions, but there was no change in binding at 5-HT(1A) autoreceptors in the DRN. Across the postsynaptic brain regions, citalopram treatment induced a mean 7% in [(11)C]CUMI-101 BP(ND) (placebo 1.3 (0.2); citalopram 1.4 (0.2); paired t-test P=0.003). The observed increase in postsynaptic [(11)C]CUMI-101 availability identified following acute citalopram administration could be attributable to a decrease in endogenous 5-HT availability in cortical terminal regions, consistent with preclinical animal studies, in which acute administration of SSRIs decreases DRN cell firing through activation of 5-HT(1A) autoreceptors to reduce 5-HT levels in postsynaptic regions. We conclude that [(11)C]CUMI-101 may be sensitive to changes in endogenous 5-HT release in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.